220 related articles for article (PubMed ID: 28703802)
1. An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells.
Jia D; Li L; Andrew S; Allan D; Li X; Lee J; Ji G; Yao Z; Gadde S; Figeys D; Wang L
Cell Death Dis; 2017 Jul; 8(7):e2932. PubMed ID: 28703802
[TBL] [Abstract][Full Text] [Related]
2. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.
Bhola NE; Balko JM; Dugger TC; Kuba MG; Sánchez V; Sanders M; Stanford J; Cook RS; Arteaga CL
J Clin Invest; 2013 Mar; 123(3):1348-58. PubMed ID: 23391723
[TBL] [Abstract][Full Text] [Related]
3. Targeting CXCR1 on breast cancer stem cells: signaling pathways and clinical application modelling.
Brandolini L; Cristiano L; Fidoamore A; De Pizzol M; Di Giacomo E; Florio TM; Confalone G; Galante A; Cinque B; Benedetti E; Ruffini PA; Cifone MG; Giordano A; Alecci M; Allegretti M; Cimini A
Oncotarget; 2015 Dec; 6(41):43375-94. PubMed ID: 26517518
[TBL] [Abstract][Full Text] [Related]
4. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms.
Singh JK; Farnie G; Bundred NJ; Simões BM; Shergill A; Landberg G; Howell SJ; Clarke RB
Clin Cancer Res; 2013 Feb; 19(3):643-56. PubMed ID: 23149820
[TBL] [Abstract][Full Text] [Related]
5. ShRNA targeting Notch1 sensitizes breast cancer stem cell to paclitaxel.
Mao J; Song B; Shi Y; Wang B; Fan S; Yu X; Tang J; Li L
Int J Biochem Cell Biol; 2013 Jun; 45(6):1064-73. PubMed ID: 23500524
[TBL] [Abstract][Full Text] [Related]
6. Autocrine control of MIP-2 secretion from metastatic breast cancer cells is mediated by CXCR2: a mechanism for possible resistance to CXCR2 antagonists.
Erin N; Nizam E; Tanrıöver G; Köksoy S
Breast Cancer Res Treat; 2015 Feb; 150(1):57-69. PubMed ID: 25682075
[TBL] [Abstract][Full Text] [Related]
7. A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Goldstein LJ; Perez RP; Yardley D; Han LK; Reuben JM; Gao H; McCanna S; Butler B; Ruffini PA; Liu Y; Rosato RR; Chang JC
Breast Cancer Res; 2020 Jan; 22(1):4. PubMed ID: 31924241
[TBL] [Abstract][Full Text] [Related]
8. Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells.
Singh JK; Simões BM; Howell SJ; Farnie G; Clarke RB
Breast Cancer Res; 2013; 15(4):210. PubMed ID: 24041156
[TBL] [Abstract][Full Text] [Related]
9. Multiple anti-tumor effects of Reparixin on thyroid cancer.
Liotti F; De Pizzol M; Allegretti M; Prevete N; Melillo RM
Oncotarget; 2017 May; 8(22):35946-35961. PubMed ID: 28415590
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-8, but not the Related Chemokine CXCL1, Sustains an Autocrine Circuit Necessary for the Properties and Functions of Thyroid Cancer Stem Cells.
Liotti F; Collina F; Pone E; La Sala L; Franco R; Prevete N; Melillo RM
Stem Cells; 2017 Jan; 35(1):135-146. PubMed ID: 27577959
[TBL] [Abstract][Full Text] [Related]
11. β-Catenin and NF-κB co-activation triggered by TLR3 stimulation facilitates stem cell-like phenotypes in breast cancer.
Jia D; Yang W; Li L; Liu H; Tan Y; Ooi S; Chi L; Filion LG; Figeys D; Wang L
Cell Death Differ; 2015 Feb; 22(2):298-310. PubMed ID: 25257174
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin triggers cancer stem cell enrichment in platinum-resistant cells through NF-κB-TNFα-PIK3CA loop.
Thakur B; Ray P
J Exp Clin Cancer Res; 2017 Nov; 36(1):164. PubMed ID: 29169370
[TBL] [Abstract][Full Text] [Related]
13. CXCR1/2 pathways in paclitaxel-induced neuropathic pain.
Brandolini L; Benedetti E; Ruffini PA; Russo R; Cristiano L; Antonosante A; d'Angelo M; Castelli V; Giordano A; Allegretti M; Cimini A
Oncotarget; 2017 Apr; 8(14):23188-23201. PubMed ID: 28423567
[TBL] [Abstract][Full Text] [Related]
14. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.
Liu X; Peng J; Sun W; Yang S; Deng G; Li F; Cheng JW; Gordon JR
Tohoku J Exp Med; 2012 Oct; 228(2):147-56. PubMed ID: 23019013
[TBL] [Abstract][Full Text] [Related]
15. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
Al-Dhfyan A; Alhoshani A; Korashy HM
Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
[TBL] [Abstract][Full Text] [Related]
16. Induction of CXCR2 ligands, stem cell-like phenotype, and metastasis in chemotherapy-resistant breast cancer cells.
Sharma B; Varney ML; Saxena S; Wu L; Singh RK
Cancer Lett; 2016 Mar; 372(2):192-200. PubMed ID: 26797460
[TBL] [Abstract][Full Text] [Related]
17. Caveolin-1 mediates chemoresistance in breast cancer stem cells via β-catenin/ABCG2 signaling pathway.
Wang Z; Wang N; Li W; Liu P; Chen Q; Situ H; Zhong S; Guo L; Lin Y; Shen J; Chen J
Carcinogenesis; 2014 Oct; 35(10):2346-56. PubMed ID: 25085904
[TBL] [Abstract][Full Text] [Related]
18. HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells.
Maxwell PJ; Gallagher R; Seaton A; Wilson C; Scullin P; Pettigrew J; Stratford IJ; Williams KJ; Johnston PG; Waugh DJ
Oncogene; 2007 Nov; 26(52):7333-45. PubMed ID: 17533374
[TBL] [Abstract][Full Text] [Related]
19. The novel inhibitor BRM270 downregulates tumorigenesis by suppression of NF-κB signaling cascade in MDR-induced stem like cancer-initiating cells.
Mongre RK; Sodhi SS; Ghosh M; Kim JH; Kim N; Park YH; Kim SJ; Heo YJ; Sharma N; Jeong DK
Int J Oncol; 2015; 46(6):2573-85. PubMed ID: 25872586
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of interleukin 8/C‑X-C chemokine receptor 1,/2 signaling reduces malignant features in human pancreatic cancer cells.
Fu S; Chen X; Lin HJ; Lin J
Int J Oncol; 2018 Jul; 53(1):349-357. PubMed ID: 29749433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
